Industries
Life Science Tools
Toutes les analyses de Life Science Tools — 14 analyses.
48/100
Danaher: Orders and Peers Make the Bioprocessing Recovery Underwritable, but 3-4% Core Growth at 23 Times Earnings Leaves No Margin of Safety
Danaher sells recurring bioprocessing, laboratory and diagnostic workflows through specialised operating companies run on the Danaher Business System, with Cytiva consumables, Cepheid cartridges and Beckman reagents supplying most of the profit pool. Second-quarter core growth was 3.0% while more than 100 million USD of chromatography-resin shipments moved into 2027, and goodwill and intangibles reached 74.5% of assets after the 9.8 billion USD Masimo purchase, against acquisition-inclusive ROIC near 6 to 7%. Rating Hold: peer consumables data make the bioprocessing recovery underwritable, but at 23.4 times guided adjusted EPS the price already pays for a conversion Danaher cannot schedule.
42/100
49Buffett
QIAGEN: Sticky Workflow Economics With Takeover Optionality Already in the Price
QIAGEN is a molecular diagnostics and life-science tools company that monetizes an entire lab workflow, from sample prep to assays, automation and bioinformatics, selling to more than 500,000 customers across five growth pillars that target about $1.61 billion of 2026 sales. The recurring consumables model is genuinely sticky, but core organic growth still needs repair while the stock carries takeover optionality after Reuters reported KKR and strategic interest. Rating Hold: at $41.51 the shares sit inside the acceptable-hold band of $39-53, above the ideal buy zone of $30-32, so buyers are paying for both a standalone repair and a deal premium that may not arrive.
45/100
Bio-Rad Laboratories: A Company in Transition, Priced Without a Margin of Safety
Bio-Rad is a diversified life-science tools and clinical-diagnostics supplier whose core operations generated 2.58 billion USD of 2025 sales, complicated by an unusually large Sartorius AG stake that dominates its GAAP earnings. Q1 2026 brought a 527.1 million USD net loss driven by a 727.7 million USD fair-value drop on the Sartorius stake, even as the operating business still produced 108.1 million USD of operating cash flow, and management cut full-year currency-neutral revenue guidance to a range of -3.0% to +0.5%. Rating Hold: durable niche assets and real asset backing, but at 297.09 USD the price already assumes the 2026 slowdown is manageable and leaves no margin of safety.
49/100
Merck KGaA : une plateforme scientifique diversifiée en transition
Merck KGaA, Darmstadt, est un groupe allemand de science et de technologie contrôlé par une famille, dont les €21.1 milliards de chiffre d'affaires 2025 proviennent de trois moteurs très différents : une branche Healthcare exposée aux brevets, une franchise Life Science d'outils de grande qualité et une activité Electronics dans les matériaux pour semi-conducteurs. En 2026, le titre est pris dans un bras de fer : la falaise de brevet connue de Mavenclad aux États-Unis pèse sur Healthcare, tandis que Process Solutions croît organiquement près de 10% et qu'Electronics profite de la demande liée à l'IA sur les noeuds avancés, laissant l'action autour de 15.9 fois l'EPS pre 2025 et d'un rendement de free cash flow de 3.5% après un rebond en mai à €133.05. Rating Conserver : les moteurs Life Science et matériaux pour semi-conducteurs sont réellement solides et compensent une branche Healthcare dont la crédibilité a été abîmée, mais la décote de gouvernance permanente de la KGaA et une valorisation seulement correcte limitent le potentiel.
51/100
Sartorius AG : une reprise de qualité dans le bioprocess déjà intégrée dans le cours
Sartorius AG est un groupe allemand d’outils pour les sciences de la vie dont la valeur est dominée par sa franchise de bioprocess détenue majoritairement, Sartorius Stedim Biotech, la ligne liquide étant l’action de préférence sans droit de vote SRT3. Après l’envolée liée à la pandémie puis le choc de déstockage, le chiffre d’affaires 2025 a rebondi de 7.6% à environ EUR 3.54 milliards, la marge d’EBITDA sous-jacent est revenue à 29.7% et l’endettement est passé de 3.96x à 3.55x, mais une dette nette d’environ EUR 3.74 milliards et un multiple encore premium de 18x l’EBITDA courant laissent peu de marge. Note Conserver : la franchise et la reprise sont réelles, mais le marché voit déjà la normalisation et le cours actuel de EUR 217.10 se situe au-dessus de la zone d’achat idéale du rapport.
42/100
Analyse approfondie de 10x Genomics
10x Genomics est une société de plateforme d'omique unicellulaire et spatiale dont le parc installé d'instruments stimule des achats récurrents de consommables à marge élevée, les consommables représentant depuis longtemps environ 84% à 86% du chiffre d'affaires. Alors que la croissance de Chromium ralentit, le prochain relais dépend d'Atera, lancé en avril 2026, mais l'entreprise reste déficitaire et environ 40% à 50% du chiffre d'affaires dépend des financements académiques et publics. Rating de recherche : Conserver ; au cours actuel de USD 28.84, l'action se traite à environ 5.1x l'EV/Sales prospectif, un niveau raisonnable mais sans marge de sécurité.
41/100
Bruker Zen Horizon Research: A Hidden Champion in Scientific Instruments, but Organic Growth Is Receding and Valuation Has Priced In the Recovery
Bruker is a hidden global champion in high-end scientific analytical instruments, with a near-oligopoly position in NMR. Organic growth has turned negative for consecutive periods, reported growth is being held up by acquisitions and FX, GAAP earnings have swung to a loss, and the profit recovery depends heavily on cost execution after a roughly 70% one-month surge left the current price of $59.97 above the average sell-side target by 16% and forward PE at about 27-28x near the top of peers. Research rating Watch: a high-quality moat business that needs either a confirmed organic inflection or a pullback toward roughly $48 to restore margin of safety.
27/100
Bio-Techne Corporation: A Deep Value Investing Study
A high-quality life-science tools company trading at a rich price. At $51.68 the stock carries a trailing P/E of roughly 74.9x while three-year revenue has compounded at only 3.3%, so the margin of safety is thin. Rating Watch: ideal entry sits at $28-35, with the roughly $1 billion Wilson Wolf follow-on acquisition as the key risk to monitor.
43/100
Revvity In-Depth Value Investment Research
Revvity is a life sciences and diagnostics tools company with understandable businesses and acceptable cash generation. The core thesis is that its recurring revenue mix and focused portfolio are attractive, but its moat and capital returns are not strong enough to offset low-single-digit GAAP ROIC, $6.6 billion of goodwill, and a share price already near the low end of the optimistic case. Research rating Watch: a quality business with insufficient margin of safety at the current price, with a fair buy range of $50 to $65.
45/100
90Buffett
Mettler-Toledo International Inc.: A Value Investing Deep Dive
A global leader in precision instruments and services with excellent quality, but at roughly $1,161 the stock trades at about 27x P/E and about 28x conservative owner earnings, already close to the optimistic scenario, so the rating is Watch; the ideal buy range is $800-950; the main risks are competition in China and emerging markets, tariff erosion of gross margin, and buybacks at high valuations.
46/100
Long-Term Research on Waters' Laboratory Analytics and Diagnostic Tools
Waters sells liquid chromatography, mass spectrometry, thermal analysis, software, consumables, and services, and after acquiring BD Biosciences it has become a life-sciences and diagnostics platform. At $342, the stock is already close to the optimistic valuation band, while the ideal buy range is $200-240. Rating Watch: a high-quality business, but current pricing leaves too little margin of safety before integration and cash-flow proof improve.
48/100
Danaher Research from a Long-Term Owner's Perspective
Danaher is a platform spanning bioprocessing, life sciences, and diagnostics, with 2025 revenue of $24.668 billion, free cash flow of roughly $5.29 billion, and recurring revenue at 82%. At the current share price of $172, the stock trades at about 23x FCF, which places it in a fair-value band without enough margin of safety. Rating Watch: a durable compounder worth studying and holding, but better approached after a wider discount emerges.
47/100
69Buffett
Thermo Fisher: A Long-Term Owner's Perspective
Thermo Fisher Scientific is a full-stack scientific infrastructure platform spanning instruments, consumables, services, CRO, and CDMO capabilities. At $448, with a static P/E of 24.6x and $65.2 billion of goodwill and acquisition-related intangibles, long-term returns depend heavily on acquisition quality and execution. Rating Watch: a high-quality business, but the current price does not offer a clearly sufficient margin of safety.
44/100
83Buffett
Agilent Technologies: A Study from a Long-Term Business Owner's Perspective
A high-quality laboratory tools and services company whose CrossLab services/consumables franchise is highly sticky, with solid cash flow and low debt. At the current $113.78, mid-single-digit growth is already fully priced in and the margin of safety is insufficient; rating Watch, with an ideal buy zone of $70-85.